Eversept Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amarin Corp
AMRN
|
+$35.2M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$25.3M |
| 3 |
OraSure Technologies
OSUR
|
+$12.9M |
| 4 |
CATALENT, INC.
CTLT
|
+$11.9M |
| 5 |
Amneal Pharmaceuticals
AMRX
|
+$7.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TG Therapeutics
TGTX
|
+$34M |
| 2 |
AstraZeneca
AZN
|
+$27.9M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$23.9M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$15.9M |
| 5 |
MYOV
Myovant Sciences Ltd.
MYOV
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.16% |
| 2 | Communication Services | 1.48% |
| 3 | Miscellaneous | 1.32% |
| 4 | Financials | 0.04% |
Similar funds
Eversept Partners's Q3 2020 Portfolio in Review
As of Q3 2020, Eversept Partners held 78 positions worth $450M, down 38% from $729M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Eversept Partners withdrew a net $152M in Q3 2020, closing 29 positions and reducing 27 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $15.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Communication Services and Miscellaneous.
Against the trend, Eversept Partners opened a new position in Teva Pharmaceutical Industries Limited worth $21.6M.
- Eversept Partners's largest Q3 2020 buy was Teva Pharmaceutical Industries Limited: 2,394,355 shares worth $21.6M.
- Eversept Partners added most to Amarin Corp in Q3 2020, an estimated $35.2M increase.
- Eversept Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $34M.
- Eversept Partners fully exited Myovant Sciences Ltd. in Q3 2020, selling an estimated $15.7M.
- Eversept Partners's ten largest holdings make up 60% of its $450M portfolio in Q3 2020.
- Eversept Partners opened 9 new positions and closed 29 in Q3 2020.
- Eversept Partners's portfolio value fell 38% quarter-over-quarter to $450M.
Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.